FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384696321> ?p ?o ?g. }

• W4384696321 abstract "Abstract Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI clinical trials and ICI are withheld from this patient group. In this retrospective multicenter study, we assessed the safety of ICI in patients with AILD. Methods We contacted tertiary referral hospitals for the identification of AILD patients under ICI treatment in Europe via the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Fourteen centers contributed data on AILD patients with malignancies being treated with ICI, another three centers did not treat these patients with ICI due to fear of irAEs. Results In this study, 22 AILD patients under ICI treatment could be identified. Among these patients, 12 had primary biliary cholangitis (PBC), five had primary sclerosing cholangitis (PSC), four had autoimmune hepatitis (AIH), and one patient had an AIH-PSC variant syndrome. Eleven patients had hepatobiliary cancers and the other 11 patients presented with non-hepatic tumors. The applied ICIs were atezolizumab (n=7), durvalumab (n=5), pembrolizumab (n=4), nivolumab (n=4), spartalizumab (n=1), and in one case combined immunotherapy with nivolumab plus ipilimumab. Among eight patients who presented with grade 1 or 2 irAEs, three demonstrated liver irAEs. Cases with grades ≥ 3 irAEs were not reported. No significant changes in liver tests were observed during the first year after the start of ICI. Conclusions This European multicenter study demonstrates that PD-1/PD-L1 inhibitors appear to be safe in patients with AILD. Further studies on the safety of more potent dual immune checkpoint therapy are needed. We conclude that immunotherapy should not categorically be withheld from patients with AILD." @default.
• W4384696321 created "2023-07-20" @default.
• W4384696321 creator A5004890730 @default.
• W4384696321 creator A5005113840 @default.
• W4384696321 creator A5010319918 @default.
• W4384696321 creator A5016466625 @default.
• W4384696321 creator A5021973999 @default.
• W4384696321 creator A5024069056 @default.
• W4384696321 creator A5029838139 @default.
• W4384696321 creator A5031269227 @default.
• W4384696321 creator A5032619196 @default.
• W4384696321 creator A5039732415 @default.
• W4384696321 creator A5042273298 @default.
• W4384696321 creator A5043324785 @default.
• W4384696321 creator A5051740312 @default.
• W4384696321 creator A5059523310 @default.
• W4384696321 creator A5061151762 @default.
• W4384696321 creator A5067553313 @default.
• W4384696321 creator A5067911784 @default.
• W4384696321 creator A5068379217 @default.
• W4384696321 creator A5077293126 @default.
• W4384696321 creator A5082873940 @default.
• W4384696321 creator A5088381041 @default.
• W4384696321 creator A5091016746 @default.
• W4384696321 creator A5091549711 @default.
• W4384696321 creator A5091564657 @default.
• W4384696321 creator A5092494175 @default.
• W4384696321 date "2023-07-18" @default.
• W4384696321 modified "2023-10-18" @default.
• W4384696321 title "PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease" @default.
• W4384696321 cites W2788726176 @default.
• W4384696321 cites W2805827066 @default.
• W4384696321 cites W2885317131 @default.
• W4384696321 cites W2915650040 @default.
• W4384696321 cites W2943781197 @default.
• W4384696321 cites W2976744492 @default.
• W4384696321 cites W2980012328 @default.
• W4384696321 cites W2994201430 @default.
• W4384696321 cites W2997079353 @default.
• W4384696321 cites W2998977965 @default.
• W4384696321 cites W3002806387 @default.
• W4384696321 cites W3013567798 @default.
• W4384696321 cites W3016972616 @default.
• W4384696321 cites W3025022288 @default.
• W4384696321 cites W3043703771 @default.
• W4384696321 cites W3048739245 @default.
• W4384696321 cites W3082973983 @default.
• W4384696321 cites W3103981458 @default.
• W4384696321 cites W3135565661 @default.
• W4384696321 cites W3159544587 @default.
• W4384696321 cites W3159787405 @default.
• W4384696321 cites W3168857062 @default.
• W4384696321 cites W3189733243 @default.
• W4384696321 cites W3207065594 @default.
• W4384696321 cites W4225394054 @default.
• W4384696321 cites W4281630496 @default.
• W4384696321 cites W4281645619 @default.
• W4384696321 cites W4282962040 @default.
• W4384696321 cites W4283717199 @default.
• W4384696321 cites W4306692674 @default.
• W4384696321 cites W4307583080 @default.
• W4384696321 cites W4310777351 @default.
• W4384696321 cites W4323308954 @default.
• W4384696321 doi "https://doi.org/10.1101/2023.07.17.23292183" @default.
• W4384696321 hasPublicationYear "2023" @default.
• W4384696321 type Work @default.
• W4384696321 citedByCount "0" @default.
• W4384696321 crossrefType "posted-content" @default.
• W4384696321 hasAuthorship W4384696321A5004890730 @default.
• W4384696321 hasAuthorship W4384696321A5005113840 @default.
• W4384696321 hasAuthorship W4384696321A5010319918 @default.
• W4384696321 hasAuthorship W4384696321A5016466625 @default.
• W4384696321 hasAuthorship W4384696321A5021973999 @default.
• W4384696321 hasAuthorship W4384696321A5024069056 @default.
• W4384696321 hasAuthorship W4384696321A5029838139 @default.
• W4384696321 hasAuthorship W4384696321A5031269227 @default.
• W4384696321 hasAuthorship W4384696321A5032619196 @default.
• W4384696321 hasAuthorship W4384696321A5039732415 @default.
• W4384696321 hasAuthorship W4384696321A5042273298 @default.
• W4384696321 hasAuthorship W4384696321A5043324785 @default.
• W4384696321 hasAuthorship W4384696321A5051740312 @default.
• W4384696321 hasAuthorship W4384696321A5059523310 @default.
• W4384696321 hasAuthorship W4384696321A5061151762 @default.
• W4384696321 hasAuthorship W4384696321A5067553313 @default.
• W4384696321 hasAuthorship W4384696321A5067911784 @default.
• W4384696321 hasAuthorship W4384696321A5068379217 @default.
• W4384696321 hasAuthorship W4384696321A5077293126 @default.
• W4384696321 hasAuthorship W4384696321A5082873940 @default.
• W4384696321 hasAuthorship W4384696321A5088381041 @default.
• W4384696321 hasAuthorship W4384696321A5091016746 @default.
• W4384696321 hasAuthorship W4384696321A5091549711 @default.
• W4384696321 hasAuthorship W4384696321A5091564657 @default.
• W4384696321 hasAuthorship W4384696321A5092494175 @default.
• W4384696321 hasBestOaLocation W43846963211 @default.
• W4384696321 hasConcept C121608353 @default.
• W4384696321 hasConcept C126322002 @default.
• W4384696321 hasConcept C197934379 @default.
• W4384696321 hasConcept C2775949291 @default.
• W4384696321 hasConcept C2776029263 @default.
• W4384696321 hasConcept C2777203481 @default.

• next